- ►annals.org RJ Barst, LJ Rubin, MD McGoon, EJ Caldwell … - Annals of internal medicine, 1994 - Am Coll Physicians Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg
Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this? ...
Objective: To evaluate the effects of long-term intravenous infusion of ... Cited by 417 - Related articles - All 7 versions
LJ Rubin, J Mendoza, M Hood, M McGoon, R … - Annals of Internal Medicine, 1990 - Am Coll Physicians Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg
Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this? ...
Study Objective: To determine the efficacy of continuous intravenous ... Cited by 390 - Related articles - All 3 versions
- ►labiomed.org [PDF] SM Shapiro, RJ Oudiz, T Cao, MA Romano, … - Journal of the American College of Cardiology, 1997 - Elsevier Methods. Patients with PPH and New York Heart Association functional class III
or IV symptoms of congestive heart failure underwent right heart catheterization
and Doppler-echocardiography to measure the maximal systolic pressure ... Cited by 222 - Related articles - BL Direct - All 14 versions
VV McLaughlin, DE Genthner, MM Panella, S … - The New England journal of medicine, 1998 - nejm.highwire.org Results We evaluated 27 patients with primary pulmonary hypertension over a mean
(±SD) period of 16.7±5.2 months. Intravenous adenosine had a variable effect
on pulmonary vascular resistance (mean reduction, 27 percent; range, 0 to ... Cited by 549 - Related articles - BL Direct - All 7 versions
RJ Barst, LJ Rubin, WA Long, MD McGoon, S … - New England Journal of Medicine, 1996 - content.nejm.org Hemodynamics improved at 12 weeks in the epoprostenol-treated patients. The
changes in mean pulmonary-artery pressure for the epoprostenol and control
groups were -8 percent and +3 percent, respectively (difference in mean ... Cited by 1399 - Related articles - BL Direct - All 9 versions
S Rich, E Kaufmann, PS Levy - New England Journal of Medicine, 1992 - content.nejm.org BACKGROUND. Primary pulmonary hypertension is a progressive, fatal disease of
unknown cause. Vasodilator drugs have been used as a treatment, but their
efficacy is uncertain. METHODS. We treated 64 patients with primary ... Cited by 1014 - Related articles - All 6 versions
- ►ahajournals.org [PDF] V Fuster, PM Steele, WD Edwards, BJ Gersh, … - Circulation, 1984 - Am Heart Assoc VALENTIN FUSTER, M. D., * PETER M. STEELE, MB B. S. (HONS.), FR AC P., ...
WILLIAM D. EDWARDS, MD, BERNARD J. GERSH, MB, CH.B., D.PHIL., MICHAEL D. MCGOON,
MD, AND ROBERT L. FRYE, MD ... ABSTRACT A long-term retrospective ... Cited by 658 - Related articles - All 5 versions
T Higenbottam, F Wells, D Wheeldon, J … - The Lancet, 1984 - Elsevier A young woman, bedbound with severe pulmonary hypertension, responded to
intravenous epoprostenol with a fall in pulmonary vascular resistance, improved
oxygenation, and a rise in exercise tolerance. For thirteen months, ... Cited by 181 - Related articles - All 5 versions
- ►utmem.edu [PDF] MM Hoeper, M Schwarze, S Ehlerding, A … - New England Journal of Medicine, 2000 - content.nejm.org Results Twenty-four patients with primary pulmonary hypertension received
aerosolized iloprost at a daily dose of 100 or 150 µg for at least one year.
The mean (±SD) distance covered in the six-minute walk test increased from ... Cited by 457 - Related articles - BL Direct - All 11 versions
- ►annals.org [PDF] DB Badesch, VF Tapson, MD McGoon, BH … - Annals of Internal Medicine, 2000 - Am Coll Physicians David B. Badesch, MD; Victor F. Tapson, MD; Michael D. McGoon, MD; Bruce H.
Brundage, MD; Lewis J. Rubin, MD; Fredrick M. Wigley, MD; Stuart Rich, MD; Robyn
J. Barst, MD; Pamela S. Barrett, PharmD; Kenneth M. Kral, MS; Maria M. ... Cited by 649 - Related articles - BL Direct - All 6 versions
